Csonka Csaba, Kupai Krisztina, Kocsis Gabriella F, Novák Gábor, Fekete Veronika, Bencsik Péter, Csont Tamás, Ferdinandy Péter
Cardiovascular Research Group, Department of Biochemistry, University of Szeged, Szeged, Hungary.
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):163-70. doi: 10.1016/j.vascn.2010.02.014. Epub 2010 Feb 25.
Ischemic heart disease is a major cause of morbidity and mortality worldwide. Myocardial ischemia followed by reperfusion results in tissue injury termed ischemia/reperfusion injury which is characterized by decreased myocardial contractile function, occurrence of arrhythmias, and development of tissue necrosis (infarction). These pathologies are all relevant as clinical consequences of myocardial ischemia/reperfusion injury and they are also important as experimental correlates and endpoints. The most critical determinant of acute and long-term mortality after myocardial infarction is the volume of the infarcted tissue. Therefore, development of cardioprotective therapies aims at reducing the size of the infarct developing due to myocardial ischemia/reperfusion injury. Different techniques are available to measure myocardial infarct size in humans and in experimental settings, however, accurate determination of the extent of infarction is necessary to evaluate interventions that may delay the onset of necrosis and/or limit the total extent of infarct size during ischemia/reperfusion. This paper highlights recent advances of the different techniques to measure infarct size.
缺血性心脏病是全球发病和死亡的主要原因。心肌缺血后再灌注会导致组织损伤,即缺血/再灌注损伤,其特征是心肌收缩功能下降、心律失常的发生以及组织坏死(梗死)的发展。这些病理情况都是心肌缺血/再灌注损伤的临床后果,并且作为实验相关因素和终点也很重要。心肌梗死后急性和长期死亡率的最关键决定因素是梗死组织的体积。因此,心脏保护疗法的发展旨在减少因心肌缺血/再灌注损伤而形成的梗死面积。在人类和实验环境中,有不同的技术可用于测量心肌梗死面积,然而,准确确定梗死范围对于评估可能延迟坏死发生和/或限制缺血/再灌注期间梗死总面积的干预措施是必要的。本文重点介绍了测量梗死面积的不同技术的最新进展。